Chimeric HLA antibody receptor T cells for targeted therapy of antibody‐mediated rejection in transplantation
Open Access
Abstract
The presence of donor‐specific antibodies (DSA), mainly against HLA, increases the risk of allograft rejection. Moreover, antibody‐mediated rejection (ABMR) remains an important barrier to optimal long‐term outcomes after solid organ transplantation. The development of chimeric autoantibody receptor T lymphocytes has been postulated for targeted therapy of autoimmune diseases. We aimed to develop a targeted therapy for DSA desensitization and ABMR, generating T cells with a chimeric HLA antibody receptor (CHAR) that specifically eliminates DSA‐producing B cells. We have genetically engineered an HLA‐A2‐specific CHAR (A2‐CHAR) and transduced it into human T cells. Then, we have performed in vitro experiments such as cytokine measurement, effector cell activation, and cytotoxicity against anti‐HLA‐A2 antibody‐expressing target cells. In addition, we have performed A2‐CHAR‐Tc cytotoxic assays in an immunodeficient mouse model. A2‐CHAR expressing T cells could selectively eliminate HLA‐A2 antibody‐producing B cells in vitro. The cytotoxic capacity of A2‐CHAR expressing T cells mainly depended on Granzyme B release. In the NSG mouse model, A2‐CHAR‐T cells could identify and eradicate HLA‐A2 antibody‐producing B cells even when those cells are localized in the bone marrow. This ability is effector:target ratio dependent. CHAR technology generates potent and functional human cytotoxic T cells to target alloreactive HLA class I antibody‐producing B cells. Thus, we consider that CHAR technology may be used as a selective desensitization protocol or an ABMR therapy in transplantation.Keywords
This publication has 47 references indexed in Scilit:
- Rapamycin and MPA, But Not CsA, Impair Human NK Cell Cytotoxicity Due to Differential Effects on NK Cell PhenotypeAmerican Journal of Transplantation, 2010
- Detection of donor-specific HLA antibodies before and after removal of a rejected kidney transplantTransplant Immunology, 2010
- Rituximab and Intravenous Immune Globulin for Desensitization during Renal TransplantationNew England Journal of Medicine, 2008
- High-resolution donor-recipient HLA matching contributes to the success of unrelated donor marrow transplantationBlood, 2007
- Detection and analysis of HLA class I and class II specific alloantibodies in the sera of dialysis recipients waiting for a renal retransplantationClinical Transplantation, 2007
- Evaluating the Survival Benefit of Kidney RetransplantationTransplantation, 2006
- Immunosuppressive Drugs and the Risk of Cancer after Organ TransplantationNew England Journal of Medicine, 2005
- Immunosuppressive Drugs for Kidney TransplantationNew England Journal of Medicine, 2004
- Impact of HLA class I and class II high-resolution matching on outcomes of unrelated donor bone marrow transplantation: HLA-C mismatching is associated with a strong adverse effect on transplantation outcomeBlood, 2004
- ACTIVATION OF ALLOREACTIVE NATURAL KILLER CELLS IS RESISTANT TO CYCLOSPORINE1Transplantation, 1997